Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNK001 allogeneic NK cell infusion with or without subcutaneous IL-2 in MDS/AML and AML
NL-OMON59206Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of RNK001 and aldesleukin in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Phase I safety and toxicity and Phase IIa clinical response. Started Jan 2025; status: completed.
02
Drugs
RNK001aldesleukin
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON59206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59206.